Pharmaceutical Industry Information Portal

Gamaleya Institute ready to file documents to test new platforms for COVID vaccines

Alexander Gintsburg said new platforms will contain antigen variants for several coronavirus variants

The Gamaleya Institute is ready to file papers to Russian Health Ministry to obtain permission for research of new platforms for COVID vaccines, Institute Director Alexander Gintsburg told TASS.

 Alexander  Gintsburg
Alexander Gintsburg
Director of the Russian Health Ministry's Gamaleya Epidemiology and Microbiology Research Institute
In order to protect ourselves from next potential mutations, we prepare new platforms that will contain antigen variants for several coronavirus variants. We already begin the submission of papers to obtain a permission for tests.

Earlier, Institute Deputy Director Denis Logunov said that the researchers were looking into development of a polyvalent vaccine against the coronavirus infection, based on several viral strains at the same time, for example, delta and omicron strains.



Expert Articles